In addition to these challenges, the interplay between aberrant epigenetic modifications and dysregulated transcriptional programs in KMT2A-rearranged AML further complicates the disease biology, limiting the scope of conventional treatment modalities [12]. This evidence concerns the gene KMT2A and acute myeloid leukemia.